Fideuram Intesa Sanpaolo Private Banking S.P.A. Has $4.08 Million Holdings in Ionis Pharmaceuticals, Inc. $IONS

Fideuram Intesa Sanpaolo Private Banking S.P.A. cut its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 55.4% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 54,269 shares of the company’s stock after selling 67,359 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A.’s holdings in Ionis Pharmaceuticals were worth $4,075,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Capital World Investors lifted its position in shares of Ionis Pharmaceuticals by 41.2% in the fourth quarter. Capital World Investors now owns 17,961,299 shares of the company’s stock valued at $1,420,918,000 after buying an additional 5,238,571 shares during the last quarter. Franklin Resources Inc. raised its stake in Ionis Pharmaceuticals by 19,941.6% in the 4th quarter. Franklin Resources Inc. now owns 1,321,345 shares of the company’s stock valued at $104,532,000 after acquiring an additional 1,314,752 shares during the period. Baker BROS. Advisors LP lifted its holdings in Ionis Pharmaceuticals by 216.1% during the 4th quarter. Baker BROS. Advisors LP now owns 1,791,841 shares of the company’s stock valued at $141,753,000 after purchasing an additional 1,225,043 shares during the last quarter. Marshall Wace LLP boosted its position in Ionis Pharmaceuticals by 7,219.3% during the third quarter. Marshall Wace LLP now owns 958,829 shares of the company’s stock worth $62,727,000 after purchasing an additional 945,729 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of Ionis Pharmaceuticals in the third quarter valued at $41,223,000. 93.86% of the stock is owned by institutional investors.

Insider Activity at Ionis Pharmaceuticals

In related news, EVP Eric Swayze sold 10,602 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $79.18, for a total transaction of $839,466.36. Following the completion of the transaction, the executive vice president directly owned 21,759 shares in the company, valued at $1,722,877.62. This represents a 32.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrick R. O’neil sold 3,069 shares of the stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $80.00, for a total transaction of $245,520.00. Following the completion of the transaction, the executive vice president directly owned 61,470 shares of the company’s stock, valued at approximately $4,917,600. The trade was a 4.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 213,029 shares of company stock worth $16,500,601 in the last ninety days. Insiders own 1.81% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on IONS shares. Oppenheimer reaffirmed an “outperform” rating and set a $111.00 target price on shares of Ionis Pharmaceuticals in a report on Thursday, April 30th. TD Cowen restated a “buy” rating and set a $108.00 price objective on shares of Ionis Pharmaceuticals in a report on Monday, June 15th. Leerink Partners increased their target price on Ionis Pharmaceuticals from $122.00 to $129.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Bank of America boosted their price target on Ionis Pharmaceuticals from $100.00 to $111.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Finally, The Goldman Sachs Group upped their price objective on Ionis Pharmaceuticals from $74.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $102.90.

Ionis Pharmaceuticals Price Performance

Shares of IONS stock opened at $81.80 on Friday. The company has a quick ratio of 4.09, a current ratio of 4.10 and a debt-to-equity ratio of 2.75. Ionis Pharmaceuticals, Inc. has a twelve month low of $40.03 and a twelve month high of $86.74. The company has a market cap of $13.52 billion, a P/E ratio of -39.52 and a beta of 0.36. The business has a fifty day simple moving average of $75.58 and a 200 day simple moving average of $77.38.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Wednesday, April 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.29. The firm had revenue of $246.09 million for the quarter, compared to analysts’ expectations of $195.56 million. Ionis Pharmaceuticals had a negative return on equity of 58.65% and a negative net margin of 30.91%.The business’s revenue for the quarter was up 86.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.93) earnings per share. On average, sell-side analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.69 EPS for the current fiscal year.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.